Pre-made Bemarituzumab benchmark antibody ( Whole mAb, anti-FGFR2 therapeutic antibody, Anti-BBDS/BEK/BFR-1/CD332/CEK3/CFD1/ECT1/JWS/K-SAM/KGFR/TK14/TK25 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Bemarituzumab biosimilar, Whole mAb, Anti-FGFR2 Antibody: Anti-BBDS/BEK/BFR-1/CD332/CEK3/CFD1/ECT1/JWS/K-SAM/KGFR/TK14/TK25 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Bemarituzumab (Amgen) is an investigational targeted antibody designed to block fibroblast growth factors from binding and activating FGFR2b. … chemotherapy alone as first-line therapy for patients with FGFR2b-positive, non-HER2-positive advanced gastric or gastroesophageal cancers.
| Products Name (INN Index) | Pre-Made Bemarituzumab biosimilar, Whole mAb, Anti-FGFR2 Antibody: Anti-BBDS/BEK/BFR-1/CD332/CEK3/CFD1/ECT1/JWS/K-SAM/KGFR/TK14/TK25 therapeutic antibody |
|---|---|
| INN Name | Bemarituzumab |
| Target | FGFR2 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2017 |
| Year Recommended | 2018 |
| Companies | Five Prime Therapeutics,ZAI Lab |
| Conditions Approved | NA |
| Conditions Active | Gastric cancer |
| Conditions Discontinued | Oesophageal cancer,Solid tumours |
| Development Tech | POTELLIGENT Technology |
| Previous Name | NA |
| Gm Offical Target Name | FGFR2 |
| Package |
